These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642 [TBL] [Abstract][Full Text] [Related]
44. Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia. Strhakova L; Bujalkova MG; Hojsikova I; Lukackova R; Behulova R; Mistrik M; Repiska V Neoplasma; 2011; 58(6):548-53. PubMed ID: 21895409 [TBL] [Abstract][Full Text] [Related]
47. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia. Baer C; Kern W; Koch S; Nadarajah N; Schindela S; Meggendorfer M; Haferlach C; Haferlach T Haematologica; 2016 Jul; 101(7):830-8. PubMed ID: 27102501 [TBL] [Abstract][Full Text] [Related]
48. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML). Wu J; Wang A; Li X; Chen C; Qi Z; Hu C; Wang W; Wu H; Huang T; Zhao M; Wang W; Hu Z; Liu Q; Wang B; Wang L; Li L; Ge J; Ren T; Xia R; Liu J; Liu Q Cancer Biol Ther; 2019; 20(6):877-885. PubMed ID: 30894066 [TBL] [Abstract][Full Text] [Related]
49. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Syed YY; McCormack PL; Plosker GL BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842 [TBL] [Abstract][Full Text] [Related]
50. [Recent Advance of Newly Therapy for Chronic Myeloid Leukemia with Lai HR; Wu QM; Yang YZ; Li J Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1579-1583. PubMed ID: 37846720 [No Abstract] [Full Text] [Related]
51. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778 [TBL] [Abstract][Full Text] [Related]
52. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386 [TBL] [Abstract][Full Text] [Related]
53. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells. Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229 [TBL] [Abstract][Full Text] [Related]
54. Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia. Gupta P; Zhang GN; Barbuti AM; Zhang X; Karadkhelkar N; Zhou J; Ding K; Pan J; Yoganathan S; Yang DH; Chen ZS Cancer Lett; 2020 Mar; 472():132-141. PubMed ID: 31837444 [TBL] [Abstract][Full Text] [Related]
55. Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms? Yap E; Tumian NR; Azma RZ; Sharifah NA; Salwati S; Hamidah NH; Elias MH; Wong CL Malays J Pathol; 2017 Aug; 39(2):107-113. PubMed ID: 28866691 [TBL] [Abstract][Full Text] [Related]
56. Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia. Mughal TI; Goldman JM Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 2():S81-4. PubMed ID: 17382017 [TBL] [Abstract][Full Text] [Related]
57. Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study. Seman ZA; Ahid F; Kamaluddin NR; Sahid ENM; Esa E; Said SSM; Azman N; Mat WKDW; Abdullah J; Ali NA; Khalid MKNM; Yusoff YM BMC Res Notes; 2024 Apr; 17(1):111. PubMed ID: 38643202 [TBL] [Abstract][Full Text] [Related]
58. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins. You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193 [TBL] [Abstract][Full Text] [Related]
59. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Roumiantsev S; Shah NP; Gorre ME; Nicoll J; Brasher BB; Sawyers CL; Van Etten RA Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10700-5. PubMed ID: 12149456 [TBL] [Abstract][Full Text] [Related]